Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label Study to Evaluate the Safety, Efficacy and Systemic Exposure of VP-102 Topical Film Forming Solution [0.7% (w/v) in Subjects (2 Years and Older) With Molluscum Contagiosum

Trial Profile

A Phase 2, Open-Label Study to Evaluate the Safety, Efficacy and Systemic Exposure of VP-102 Topical Film Forming Solution [0.7% (w/v) in Subjects (2 Years and Older) With Molluscum Contagiosum

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2018

At a glance

  • Drugs Cantharidin (Primary)
  • Indications Molluscum contagiosum
  • Focus Therapeutic Use
  • Acronyms Innovate
  • Sponsors Verrica Pharmaceuticals
  • Most Recent Events

    • 12 Sep 2018 Results published in the Verrica Pharmaceuticals Media Release
    • 12 Sep 2018 Status changed from recruiting to completed.
    • 07 Aug 2018 According to a Verrica Pharmaceuticals media release, complete clinical results from enrolled patients expected in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top